Efficacy and safety of arbekacin for staphylococcal infection in the NICU

Pediatrics International

Volumn 45, Issue 3, 2003, Pages 301-306

  Suzuki, Keiji ^a,b  

^a ST MARIANNA UNIVERSITY   (Japan)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Arbekacin; Coagulase negative staphylococci; Low birthweight infant; Methicillin resistant Staphylococcus aureus; Newborn

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CREATININE; HABEKACIN; SULTAMICILLIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; AUDITORY RESPONSE; BACTERIUM ISOLATE; BRAIN STEM RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; DRUG SAFETY; HUMAN; INFANT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; NEWBORN INTENSIVE CARE; OTOTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CREATININE; CROSS INFECTION; DIBEKACIN; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 0042163104     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.2003.01722.x     Document Type: Article

References (21)

1. Uehara Y, Kikuchi K, Nakamura T et al. Inhibition of methicillin-resistant Staphylococcus aureus colonization of oral cavities in newborns by viridans group streptococci. Clin. Infect. Dis. 2001; 32: 1399-407.
2. Back NA, Linnemann CC Jr, Staneck JL, Kotagal UR. Control of methicillin-resistant Staphylococcus aureus in a neonatal intensive-care unit: Use of intensive microbiologic surveillance and mupirocin. Infect. Cont. Hosp. Epidemiol. 1996; 17: 227-31.
3. Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988-1997, and the impact of avoiding empiric vancomycin therapy. Pediatr. 2000; 106: 1387-90.
4. Sung L, Rmotar K, Samson LM, Toye B. Bacteremia due to persistent strains of coagulase-negative staphylococci in a neonatal intensive-care unit. Infect. Cont. Hosp. Epidemiol. 1999; 20: 349-51.
5. Berger A, Salzer HR, Weninger M, Sageder B, Aspock C. Septicaemia in an Austrian neonatal intensive unit: a 7-year analysis. Act. Paediatr. 1998; 87: 1066-9.
6. Fanos V, Dall'Agnola A. Antibiotics in neonatal infections: a review. Drugs 1999; 58: 405-27.
7. Kondo S, Inuma K, Yamamoto K, Maeda K, Umezawa H. Syntheses of 1-N-{(S)-4-amino-2-hydroxybutyryl}-kanamycin B and - 3′,4′-dideoxykanamaycin B active against kanamycin-resistant bacteria. J. Antibiot. 1973; 26: 412-15.
8. Inoue M, Nonoyama M, Okamoto R, Ida T. Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic against methicillin-resistant Staphylococcus aureus. Drugs Exp. Clin. Res. 1994; 20: 233-40.
9. Watanabe T, Ohashi K, Matsui K, Kubota T. Comparative studies of the bactericidal morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 1997; 39: 471-6.
10. Fujii R, Kobayashi Y, Nishimura T et al. Guidelines for assessment of clinical tests of antimicrobial agents in neonatal field. Japan J. Antibiot. 1996; 49: 744-53 [in Japanese].
11. Fujii R, Sunakawa K, Nishimura T et al. Clinical studies of arbekacin sulfate in the pediatric field. Japan J. Antibiot. 1994; 47: 57-83 [in Japanese].
12. Sakata H, Maruyama S, Ishioka T et al. Pharmacokinetics and influence of arbekacin on renal function in low-birthweight infants. J. Infect. Chemother. 1997; 3: 160-3.
13. Deguchi K, Suzuki Y, Ishihara R et al. Antimicrobial activities of arbekacin against methicillin-resistant Staphylococcus aureus. Japan J. Antibiot. 1997; 50: 1-11 [in Japanese].
14. Hamilton-Miller JMT, Shah S. Activity of the semi-synthetic kanamycin B derivative, arbekacin, against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 1995; 35: 865-8.
15. Tomono N, Nakayoshi T, Shinkai S, Fujita M. Pharmacokinetics of arbekacin in dogs. II. The distribution of arbekacin in tissues. Japan J. Antibiot. 1987; 40: 377-84. [in Japanese]
16. Deguchi K, Yokota N, Koguchi M et al. Antibiotic efficacies of combined uses of arbekacin and various antibiotics against methicillin-resistant Staphylococcus aureus. Japan J. Antibiot. 1994; 47: 693-700 [in Japanese].
17. Asada K, Inaba Y, Hiramatsu K et al. Evolution and resistance expression of MRSA. Evaluation of β-lactam antibiotics against a set of isogenic strains with different types of phenotypic expression. Acta Biochimica Polonica 1995; 42: 517-24.
18. Rolinson GN. Evolution of beta-lactamase inhibitors. Rev. Infect. Dis. 1991; 13 (Suppl. 9): S727-32.
19. Schacht J, Weiner N. Aminoglycoside-induced hearing loss: a molecular hypothesis. ORL 1986; 48: 116-23.
20. De Broe ME, Paulus GJ, Verpooten GA et al. Early effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney Internat. 1984; 25: 643-52.
21. 1-microglobulin. Pediatr. Nephrol. 1996; 10: 645-7.